ZLAB Stock Analysis: Zai Lab | NASDAQ

Biotechnology | NASDAQ, USA | Market Cap: 3.071m USD | 12M Return: 12.5% | US98887Q1040 | Charts, Fundamentals & Technical Analysis

Oncology, Immunology, Neuroscience, Infectious Diseases
Total Rating 26
Safety 27
Buy Signal -0.14
Biotechnology
Sub-Industry Rotation: +4.6
Market Cap: 3.07B
Avg Turnover: 27.7M
Risk 3d forecast
Volatility59.9%
VaR 5th Pctl10.0%
VaR vs Median1.79%
Reward TTM
Sharpe Ratio0.41
Rel. Str. IBD68.5
Rel. Str. Peer Group54.8 pctl
Character TTM
Beta0.751
Beta Downside0.952
Hurst Exponent0.532
Choppyness78.8%
Drawdowns 3y
Max DD62.12%
CAGR/Max DD-0.08
CAGR/Mean DD-0.15
EPS (Earnings per Share) EPS (Earnings per Share) of ZLAB over the last years for every Quarter: "2021-09": -1.01, "2021-12": -2.17, "2022-03": -0.86, "2022-06": -1.44, "2022-09": -1.68, "2022-12": -0.65, "2023-03": -0.51, "2023-06": -1.25, "2023-09": -0.71, "2023-12": -0.98, "2024-03": -0.5, "2024-06": -0.82, "2024-09": -0.42, "2024-12": -0.8, "2025-03": -0.45, "2025-06": -0.37, "2025-09": -0.33, "2025-12": -0.46, "2026-03": -0.46, "2026-06": -0.46, "2026-09": -0.41,
Last SUE: 0.99
Qual. Beats: 2
Revenue Revenue of ZLAB over the last years for every Quarter: 2021-09: 43.103, 2021-12: 44.171, 2022-03: 46.724, 2022-06: 48.176, 2022-09: 57.54, 2022-12: 62.601, 2023-03: 62.797, 2023-06: 68.864, 2023-09: 69.228, 2023-12: 65.83, 2024-03: 87.149, 2024-06: 100.504, 2024-09: 102.265, 2024-12: 109.07, 2025-03: 106.487, 2025-06: 109.977, 2025-09: 116.095, 2025-12: 127.597, 2026-03: 99.611, 2026-06: 106.311, 2026-09: 108.208,
Rev. CAGR: 20.71%
Rev. Trend: 90.2%
Last SUE: 0.03
Qual. Beats: 0

Warnings

Interest Coverage Ratio Critical
Altman Z'' In Financial Distress Zone
Choppy
Below Avwap Earnings

Tailwinds

Confidence

Seasonality 9.1 years of data, until 10/2026

Jan +12.8% 0
Feb +1.6% 0
Mar -1.8% 10
Apr +6.4% 0
May -1.4% 0
Jun +4.3% 25
Jul -0.9% 0
Aug +0.5% 0
Sep -2.6% 10
Oct -4.2% 4
Nov +10.6% 10
Dec -1.6% 0

How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, ≥40 worth a closer look and ≥60 is strong.

Description: ZLAB Zai Lab

Zai Lab Limited is a Shanghai- and Pudong-based biopharmaceutical company that discovers, develops, and commercializes therapies in oncology, immunology, neuroscience, and infectious diseases. Founded in 2013 and listed on NASDAQ in 2017, the company generates revenue through a portfolio of commercialized drugs-including Zejula, VYVGART, NUZYRA, Optune, Qinlock, Xacduro, and Augtyro-spanning ovarian cancer, myasthenia gravis, bacterial infections, glioblastoma, gastrointestinal stromal tumors, and non-small cell lung cancer.

Its business model combines in-licensed products from global partners with internal R&D, supported by a network of strategic collaborations with Tesaro, NovoCure, Deciphera Pharmaceuticals, Paratek, argenx, Turning Point Therapeutics, Entasis Therapeutics, Karuna Therapeutics, Pfizer, Amgen, and Boehringer Ingelheim. Such licensing and co-development agreements are a common structure for China-based biotechs, which typically leverage in-licensed late-stage assets to accelerate commercialization domestically while developing their own pipeline for global markets.

Headlines to Watch Out For
  • VYVGART launch in China drives immunology segment revenue growth
  • NRDL price negotiations pressure margins on Zejula and portfolio drugs
  • Pipeline catalysts from Pfizer and Amgen collaborations expand oncology and immunology pipeline
Piotroski VR-10 (Strict) 1.0
Net Income: -198.4m TTM > 0 and > 6% of Revenue
FCF/TA: -0.18 > 0.02 and ΔFCF/TA -0.24 > 1.0
NWC/Revenue: 99.64% < 20% (prev 152.4%; Δ -52.79% < -1%)
CFO/TA -0.16 > 3% & CFO -159.2m > Net Income -198.4m
Net Debt/EBITDA: error (EBITDA <= 0)
Current Ratio: 2.04 > 1.5 & < 3
Outstanding Shares: last quarter (112.3m) vs 12m ago 1.94% < -2%
Gross Margin: 54.69% > 18% (prev 61.32%; Δ -6.62% > 0.5%)
Asset Turnover: 40.47% > 50% (prev 38.11%; Δ 2.37% > 0%)
Interest Coverage Ratio: -31.91 > 6 (EBIT TTM -196.6m / Interest Expense TTM 6.16m)
Altman Z'' -5.95
A: 0.43 (Total Current Assets 864.4m - Total Current Liabilities 424.2m) / Total Assets 1.02b
B: -2.71 (Retained Earnings -2.78b / Total Assets 1.02b)
C: -0.18 (EBIT TTM -196.6m / Avg Total Assets 1.09b)
D: 1.22 (Book Value of Equity 563.3m / Total Liabilities 460.6m)
Altman-Z'' = -5.95 = D
Beneish M -2.67
DSRI: 0.72 (Receivables 75.4m/105.0m, Revenue 441.7m/441.6m)
GMI: 1.12 (GM 61.32% / 54.69%)
AQI: 1.82 (AQ_t 0.10 / AQ_t-1 0.05)
SGI: 1.00 (Revenue 441.7m / 441.6m)
TATA: -0.04 (NI -198.4m - CFO -159.2m) / TA 1.02b)
Beneish M = -2.67 (Cap -4..+1) = A
What is the price of ZLAB shares?

As of November 18, 2026, the stock is trading at USD 23.53 with a total of 690,592 shares traded. Over the past week, the price has changed by -10.97%, over one month by -2.20%, over three months by -8.23% and over the past year by +12.48%.

Current recommended Stop Loss: 19.90 (which is 15.4% or 2.4 ATR below the current price).

Is ZLAB a buy, sell or hold?

Zai Lab has received a consensus analysts rating of 4.67. Therefore, it is recommended to buy ZLAB.

  • StrongBuy: 9
  • Buy: 2
  • Hold: 1
  • Sell: 0
  • StrongSell: 0

What are the forecasts/targets for the ZLAB price?
Analysts Target Price 34.1 45%
Zai Lab (ZLAB) - Fundamental Data Overview as of 15 November 2026
Market Cap USD = 3.07b (3.07b USD * 1.0 USD.USD)
P/S = 6.9526
P/B = 5.7692
Revenue TTM = 441.7m USD
EBIT TTM = -196.6m USD
EBITDA TTM = -180.2m USD
Long Term Debt = 9.56m USD (estimated: total debt 267.4m - short term 257.9m)
Short Term Debt = 257.9m USD (from shortTermDebt, last quarter)
Debt = 282.5m USD (from shortLongTermDebtTotal, last quarter) + Leases 15.1m
Net Debt = -277.1m USD (calculated: Debt 282.5m - CCE 559.7m)
Enterprise Value = 2.79b USD (3.07b + Debt 282.5m - CCE 559.7m)
Interest Coverage Ratio = -31.91 (Ebit TTM -196.6m / Interest Expense TTM 6.16m)
EV/FCF = -15.09x (Enterprise Value 2.79b / FCF TTM -185.2m)
FCF Yield = -6.63% (FCF TTM -185.2m / Enterprise Value 2.79b)
FCF Margin = -41.93% (FCF TTM -185.2m / Revenue TTM 441.7m)
Net Margin = -44.91% (Net Income TTM -198.4m / Revenue TTM 441.7m)
Gross Margin = 54.69% ((Revenue TTM 441.7m - Cost of Revenue TTM 200.1m) / Revenue TTM)
Gross Margin QoQ = 52.59% (prev 54.70%)
Tobins Q-Ratio = 2.73 (Enterprise Value 2.79b / Total Assets 1.02b)
Interest Expense / Debt = 2.18% (Interest Expense 6.16m / Debt 282.5m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -155.3m (EBIT -196.6m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 2.04 (Total Current Assets 864.4m / Total Current Liabilities 424.2m)
Debt / Equity = 0.50 (Debt 282.5m / totalStockholderEquity, last quarter 563.3m)
 Debt / EBITDA = 1.54 (negative EBITDA) (Net Debt -277.1m / EBITDA -180.2m)
 Debt / FCF = 1.50 (negative FCF - burning cash) (Net Debt -277.1m / FCF TTM -185.2m)
 Total Stockholder Equity = 636.9m (last 4 quarters mean from totalStockholderEquity)
RoA = -18.18% (Net Income -198.4m / Total Assets 1.02b)
RoE = -31.15% (Net Income TTM -198.4m / Total Stockholder Equity 636.9m)
RoCE = -30.41% (EBIT -196.6m / Capital Employed (Equity 636.9m + L.T.Debt 9.56m))
 RoIC = -18.59% (negative operating profit) (NOPAT -155.3m / Invested Capital 835.5m)
 WACC = 7.63% (E(3.07b)/V(3.35b) * Re(8.17%) + D(282.5m)/V(3.35b) * Rd(2.18%) * (1-Tc(0.21)))
Discount Rate = 8.17% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -69.14 | Cagr: -61.74%
 [DCF] Fair Price = unknown (Cash Flow -185.2m)
 EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.99 | # QB: 2
Revenue Correlation: 90.18 | Revenue CAGR: 20.71% | SUE: 0.03 | # QB: 0
EPS current Quarter (2027-03-31): EPS=-0.43 | Chg30d=+17.92% | Revisions=+25% | Analysts=2
EPS current Year (2026-12-31): EPS=-1.88 | Chg30d=+14.55% | Revisions=+17% | GrowthEPS=-17.3% | GrowthRev=-4.6%
EPS next Year (2027-12-31): EPS=-1.98 | Chg30d=+6.04% | Revisions=+17% | GrowthEPS=-5.7% | GrowthRev=+22.4%
[Analyst] Revisions Ratio: +30% (up=5, down=2)